Targeted treatments for lung cancer

Monday 08 April 2019, Royal Marsden Hospital London

Description: In this course I describe the faulty genes, pathways and proteins that drive small cell and non-small cell lung cancer. I also explain the scientific rationale behind targeted treatments in use and in development for these diseases, such as EGFR inhibitors, ALK inhibitors, B-Raf inhibitors, angiogenesis inhibitors and immunotherapy with checkpoint inhibitors.

Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.

To book, contact: conferenceteam@rmh.nhs.uk, or call: 020 7808 2922

Programme:

Introduction to lung cancer: a disease of many layers
  • The role of DNA damage & epigenetics in cancer development
  • Cancer cells and their microenvironment
  • Genetic instability and intra-tumoural heterogeneity
  • An introduction to cell signalling
  • Monoclonal antibodies and kinase inhibitors: spot the difference
Introducing non-small cell lung cancer
  • Mechanisms of development
  • The molecular landscape of adenocarcinoma and squamous cell carcinoma
  • The role of the EGF-Receptor in NSCLC
Targeted treatments for non-small cell lung cancer
  • 1st, 2nd and 3rd generation EGF-R targeted treatments (gefitinib, erlotinib, afatinib, dacomitinib, neratinib, rociletinib, osimertinib)
  • ALK inhibitors (crizotinib, ceritinib, alectinib)
  • Angiogenesis inhibitors
  • More targets and treatments: B-Raf, PI3K, ROS1 & MEK inhibitors
Molecular pathology and targeted treatments for small cell lung cancer
  • The cellular & molecular landscape of small cell lung cancer
  • Targeted treatment approaches for small cell lung cancer
Immunotherapy approaches for lung cancer & current trials
  • Checkpoint inhibitors (CTLA-4, PD-1 and PD-L1 monoclonal antibodies)
  • Current trials